Azenta (AZTA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from Needham reiterated a Buy rating on the stock and has a $40.00 price target.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
David Saxon has given his Buy rating due to a combination of factors, including Azenta’s strong financial performance in the second quarter of fiscal year 2025. The company’s revenue and EBITDA exceeded market expectations, and management has maintained its guidance for the full fiscal year. This indicates a robust operational execution despite challenging macroeconomic conditions.
Additionally, Saxon notes that Azenta’s strategic initiatives have minimized the impact of funding dynamics on revenue and margins. The strength in the company’s SMS segment and growth in Multiomics, particularly driven by next-generation sequencing (NGS), further support the positive outlook. An upcoming Investor Day is anticipated to provide more clarity on Azenta’s long-term growth and profitability, reinforcing the Buy rating, although the price target has been adjusted to $40 due to lower peer multiples.